Linprixel for relapsed autoimmune hemolytic anemia
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests a new drug called linprixel for people with autoimmune hemolytic anemia (AIHA) that has not responded to or has come back after at least two earlier treatments. The goal is to see if linprixel can help control the disease and improve blood counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need a confirmed diagnosis of warm AIHA, cold AIHA, or Evans syndrome (or AIHA linked to a connective tissue disease like lupus).
- You must have already tried at least two standard treatments (like steroids, rituximab, or other immune-suppressing drugs) without success or with relapse.
- Your hemoglobin level must be 10 g/dL or lower at the start of the study.
- You cannot have serious infections (like HIV, hepatitis B or C), uncontrolled cancer, or major organ failure.
- You must be willing to stop certain other treatments (like steroids or immune-suppressing drugs) for a period before and during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine for people with autoimmune hemolytic anemia (AIHA) that has not improved with standard treatments. The goal is to see if the drug can help control the disease and improve red blood cell counts.
This study tests a new drug called enatumab that may help people with a type of autoimmune anemia where the body attacks its own red blood cells. If you have not responded to previous treatments or your condition has returned, this trial might offer a new option to improve your hemoglobin levels.
This trial tests a new type of cell therapy (called CAR-T) for people with autoimmune hemolytic anemia or Evans syndrome that has not improved with standard treatments. The goal is to see if this therapy can control the condition and reduce the need for ongoing immune-suppressing drugs.
This study tests an experimental cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) or Evans syndrome that has not improved with standard treatments. The goal is to see if this therapy can help control the anemia and reduce the need for ongoing treatments.
This Phase 2 trial tests whether taking long-term apixaban (a blood thinner) can prevent venous blood clots in people with autoimmune hemolytic anemia (AIHA). It may help reduce the risk of dangerous clotting events if you meet safety and risk criteria.
This early-phase study tests a new drug called CC312 in patients with certain autoimmune diseases like lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia. The goal is to see if it's safe and how the body handles it.
Hear when a new Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.